文献速递肥胖与代谢综合征性腺与生殖内分泌骨质疏松与钙磷/甲状旁腺

生活方式干预联合睾酮替代治疗对老年肥胖性腺功能减退男性的影响

Testosterone Replacement Therapy Added to Intensive Lifestyle Intervention in Older Men With Obesity and Hypogonadism.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

这项随机双盲安慰剂对照试验纳入83例65岁以上肥胖(BMI≥30 kg/m2)且睾酮持续偏低(<10.4 nmol/L)的衰弱男性,比较生活方式治疗联合睾酮或安慰剂6个月的效果。结果显示两组躯体功能评分(PPT)改善相似(17% vs 16%,P=0.58),但联合睾酮组VO2peak提升更明显、瘦体重和髋部骨密度丢失更少、红细胞压积升高更显著。

要点

  • 在生活方式干预基础上加用睾酮6个月未进一步改善老年肥胖性腺功能减退男性的整体躯体功能。
  • 联合睾酮可减轻减重导致的瘦体重和髋部骨密度下降,并可能改善有氧能力。
  • 联合睾酮组红细胞压积升高更明显,需监测相关安全性指标。

核心结论

  • 在老年肥胖性腺功能减退男性中,生活方式治疗加用睾酮6个月未进一步改善整体躯体功能。
  • 但睾酮可能减轻减重引起的肌肉量和髋部骨密度下降,并可能进一步改善有氧能力。

研究设计与样本

  • 随机双盲安慰剂对照试验,在VA医疗中心开展。
  • 纳入83例年龄≥65岁、肥胖(BMI≥30 kg/m2)且晨间睾酮持续偏低(<10.4 nmol/L)并伴衰弱的男性。
  • 参与者随机接受生活方式治疗(体重管理和运动训练)联合睾酮或安慰剂,为期6个月。

主要发现

  • 主要结局PPT评分在联合睾酮组和联合安慰剂组改善相似(17% vs 16%;P=0.58)。
  • VO2peak在联合睾酮组增加更明显(23% vs 16%;P=0.03)。
  • 两组体重下降均约9%,但联合睾酮组瘦体重下降更少(-2% vs -3%;P=0.01),大腿肌肉体积下降也更少(-2% vs -4%;P=0.04)。
  • 髋部骨密度在联合睾酮组得以保持,而联合安慰剂组下降(0.5% vs -1.1%;P=0.003)。
  • 肌力增加两组相似(23% vs 22%;P=0.94);红细胞压积在联合睾酮组升高更明显(5% vs 1%;P<0.001),PSA无显著差异;睾酮水平升高更明显(167% vs 27%;P<0.001)。

临床怎么用

  • 对老年肥胖性腺功能减退男性,在生活方式干预基础上加用睾酮应以改善身体成分和骨密度为目标,而非期望额外提升整体躯体功能。
  • 联合睾酮治疗期间需监测红细胞压积变化。

局限性

  • 样本量83例,研究周期6个月,长期疗效和安全性未明确。
  • 研究在单一VA医疗中心开展,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity and hypogonadism additively contribute to frailty in older men; however, appropriate treatment remains controversial. OBJECTIVE: Determine whether testosterone replacement augments the effect of lifestyle therapy on physical function in older men with obesity and hypogonadism. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: VA Medical Center. PARTICIPANTS: 83 older (age ≥65 years) men with obesity (body mass index ≥30 kg/m2) and persistently low am testosterone (<10.4 nmol/L) associated with frailty. INTERVENTIONS: Participants were randomized to lifestyle therapy (weight management and exercise training) plus either testosterone (LT+Test) or placebo (LT+Pbo) for 6 months. OUTCOME MEASURES: Primary outcome was change in Physical Performance Test (PPT) score. Secondary outcomes included other frailty measures, body composition, hip bone mineral density (BMD), physical functions, hematocrit, prostate specific antigen (PSA), and sex hormones. RESULTS: PPT score increased similarly in LT+Test and LT+Pbo group (17% vs. 16%; P = 0.58). VO2peak increased more in LT+Test than LT+Pbo (23% vs. 16%; P = 0.03). Despite similar -9% weight loss, lean body mass and thigh muscle volume decreased less in LT+Test than LT+Pbo (-2% vs. -3%; P = 0.01 and -2% vs -4%; P = 0.04). Hip BMD was preserved in LT+Test compared with LT+Pbo (0.5% vs -1.1%; P = 0.003). Strength increased similarly in LT+Test and LT+Pbo (23% vs 22%; P = 0.94). Hematocrit but not PSA increased more in LT+Test than LT+Pbo (5% vs 1%; P < 0.001). Testosterone levels increased more in LT+Test than LT+Pbo (167% vs 27%; P < 0.001). CONCLUSION: In older, obese hypogonadal men, adding testosterone for 6 months to lifestyle therapy does not further improve overall physical function. However, our findings suggest that testosterone may attenuate the weight loss-induced reduction in muscle mass and hip BMD and may further improve aerobic capacity.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Barnouin Y, Armamento-Villareal R, Celli A, et al. Testosterone Replacement Therapy Added to Intensive Lifestyle Intervention in Older Men With Obesity and Hypogonadism. J Clin Endocrinol Metab. 2021. PMID: 33351921. doi:10.1210/clinem/dgaa917

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。